APAC TAVR Market

APAC TAVR Market Size (2022 to 2027)

The size of the Asia Pacific Transcatheter Aortic Valve Replacement Market is estimated to be worth USD 1.30 billion by 2027 from USD 0.50 billion in 2022, growing at a CAGR of 21.20% between 2022 to 2027.

The APAC Transcatheter aortic valve replacement (TAVR) market is expected to be driven by growth factors such as the increasing prevalence of cardiovascular disorders such as heart failure, congestive heart failure, mitral regurgitation coronary artery disease, severe aortic stenosis, and hypertension. Cardiovascular disease causes the aortic valve to malfunction, fueling the demand for an effective valve replacement procedure. In addition, the elderly population is prone to cardiovascular diseases and vascular complications arising from other chronic diseases. For example, about 5% of the world's population is over 65 and at risk of developing heart valve disease. India's senior population aged above 60 is expected to reach 195 million in 2031 from over 139 million by the end of 2022, an increase of 42% has been recorded over the past decade, according to the National Statistics Office of India report.

Factors such as the increasing obese population, higher risk in diabetic patients, and growing inoperable aortic stenosis are other factors driving the APAC TAVR market. Furthermore, increasing technological advancements and increased demand for minimally invasive catheter-based procedures over conventional open-heart therapies and patients opting for effective and efficient treatment with rapid recovery are driving the market growth. In addition, TAVR in the older population as the open-heart procedure is too risky for them, and the next best alternative is to undergo TAVR.

However, factors such as the high price of TAVR procedures and the limited adoption of the TAVR systems in the APAC population are limiting the growth of the studied market. For now, there are around 257 centers where TAVR is performed in Asia. In addition, the low adoption can be attributed to the high-grade technology required to perform such surgery, which needs a team including skilled interventionists, cardiac-thoracic surgeons, radiologists, and echocardiographs. These factors collectively are limiting the market growth rate in most Asian countries.

In India, the TAVR procedure is carried out at around 30 centers. This is well below the total number of cardiac surgeries needed to be formed in the region. There is a lack of availability of skilled doctors, and poor medical facilities, complex approval systems by regulatory bodies, and the lack of specialized training programs.

This research report on the Asia Pacific TAVR Market has been segmented and sub-segmented into the following categories:

By Surgery Method:

• Transfemoral Implantation
• Transapical Implantation
• Transaortic Implantation
• Transvaal Implantation                  

By Valve Material:

• Nitinol
• Stainless Steel
• Cobalt-Chromium              

By Valve Size:

• 14mm to 18 mm
• 18mm to 22 mm
• 22mm to 29mm                    

By Valve Leaflets Material:

• Bovine Heart Tissue
• Cow Heart Tissue
• Other Valve Leaflets Material                       

By End Users:

• Hospitals
• Ambulatory Surgical Centres
• Cardiac Catheterization Laboratories     

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

During the forecast period, the APAC TAVR market is expected to be dominated by Japan. This regional market is estimated to exceed over $ 452 million by 2027, due to an increasing prevalence of aortic stenosis in the elderly, according to a report by global data. During the year 2020, Japan accounted for over60% of the TAVR procedures in the APAC region. Factors such as a large elderly patient base, preference for minimally invasive procedures, increased awareness and training of physicians, and advanced devices are driving the Japan TAVR market. Over 43.5 million of the Japanese population are 60 years of age or older. Although TAVR procedures are primarily performed in the 75 and older age group in Japan, the number is expected to go over 21% over the next five years, while currently, less than 11% of patients treated with TAVR are under 75 years of age. In the elderly population, healthcare professionals prefer TAVR to surgical aortic valve replacement for aortic stenosis because of short hospital stay, speedy recovery, low risk of exposure to infections and complications.

India is the fastest-growing country in the APAC TAVR market and is expected to grow at a CAGR of 29.9% during the projected period 2022 to 2027.  Factors such as increased healthcare spending, application of TAVR systems across the region, large patient base, improving healthcare facilities in the Indian TAVR market are expected to provide several opportunities for growth for the market during the forecast period.

KEY MARKET PLAYERS:

Companies playing a promising role in the Asia Pacific Transcatheter Aortic Valve Replacement (TAVR) Market profiled in this report are Edwards Lifesciences Corporation (U.S.), Medtronic, Inc. (Ireland), Boston Scientific Corporation (U.S.), Abbott Laboratories (U.S.), St. Jude Medical Inc. (U.S.), JenaValve Technology, Inc. (Germany), Symetis SA (Switzerland), Direct Flow Medical, Inc. (U.S.), Sorin Group (Italy), Meril Life Sciences India Pvt Ltd (India) and Braile Biomedica (Brazil).